RxDoctor Payments Data

Tristan Petrie, MD

Cardiovascular Disease · Syracuse, NYNPI 1548604507

Payments from drug & device makers

$16,485in general payments, 2019–2025

Across 94 payments — averaging $175.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • Abbott$2K
  • Abiomed$2K
  • AstraZeneca$403
  • Novartis$393
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$317
  • plus $982 from 10 others

What the payments were for

  • Speaking & faculty fees$10,15062%
  • Travel & lodging$2,34014%
  • Food & beverage$3,84623%
  • Education$1491%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,485 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$183,576
Medicare patients
832
Services billed
3,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$449,869
JardianceEmpagliflozin212$171,997
EntrestoSacubitril/Valsartan119$136,827
XareltoRivaroxaban49$73,131
Repatha SureclickEvolocumab52$51,694
Ambrisentan13$36,824
Metoprolol Succinate391$4,158
Ranolazine ErRanolazine43$3,376
Atorvastatin Calcium297$2,553
Nifedipine ErNifedipine61$1,724
Carvedilol258$1,628
Flecainide Acetate30$1,570
Spironolactone240$1,386
Rosuvastatin Calcium143$1,234
Losartan Potassium116$1,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$10,713$449,869409 claims
Boehringer IngelheimJardiance$27$171,997212 claims
NovartisEntresto$393$136,827119 claims
Johnson & JohnsonXarelto$275$73,13149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →